Galera Therapeutics Analyst Ratings
Galera Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 23.58% | Citigroup | $0.4 → $0.25 | Maintains | Neutral |
| 08/16/2023 | 48.29% | HC Wainwright & Co. | $6 → $0.3 | Downgrades | Buy → Neutral |
| 08/10/2023 | 147.16% | Piper Sandler | $6 → $0.5 | Downgrades | Overweight → Neutral |
| 07/17/2023 | 2865.89% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/22/2023 | 2865.89% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 02/21/2023 | 2865.89% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 02/16/2023 | 3360.21% | B of A Securities | $2 → $7 | Upgrades | Underperform → Buy |
| 02/16/2023 | 4843.15% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/27/2022 | 888.63% | B of A Securities | → $2 | Downgrades | Neutral → Underperform |
| 12/20/2021 | 9786.31% | Citigroup | $11 → $20 | Maintains | Buy |
| 12/15/2021 | 4843.15% | HC Wainwright & Co. | → $10 | Upgrades | Neutral → Buy |
| 12/15/2021 | 7314.73% | BTIG | → $15 | Upgrades | Neutral → Buy |
| 10/20/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/19/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/16/2020 | 7314.73% | Credit Suisse | $9 → $15 | Upgrades | Neutral → Outperform |
| 12/07/2020 | 7314.73% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 11/11/2020 | 4348.84% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 07/29/2020 | 3854.52% | Credit Suisse | $14 → $8 | Maintains | Neutral |
| 12/02/2019 | 14729.46% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 12/02/2019 | 7314.73% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 12/02/2019 | 9786.31% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 6820.42% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月29日 | 23.58% | 花旗集团 | $0.4→$0.25 | 维护 | 中性 |
| 08/16/2023 | 48.29% | HC Wainwright公司 | $6→$0.3 | 评级下调 | 购买→中性 |
| 2023年08月10日 | 147.16% | 派珀·桑德勒 | $6→$0.5 | 评级下调 | 超重→中性 |
| 07/17/2023 | 2865.89% | HC Wainwright公司 | →$6 | 重申 | 购买→购买 |
| 03/22/2023 | 2865.89% | HC Wainwright公司 | $10→$6 | 维护 | 买 |
| 02/21/2023 | 2865.89% | 派珀·桑德勒 | →$6 | 开始承保 | →超重 |
| 02/16/2023 | 3360.21% | B of A证券 | $2→$7 | 升级 | 表现不佳的→收购 |
| 02/16/2023 | 4843.15% | HC Wainwright公司 | →$10 | 重申 | →购买 |
| 2022年05月27日 | 888.63% | B of A证券 | →$2 | 评级下调 | 中性→表现不佳 |
| 12/20/2021 | 9786.31% | 花旗集团 | $11→$20 | 维护 | 买 |
| 2021年12月15日 | 4843.15% | HC Wainwright公司 | →$10 | 升级 | 中性→购买 |
| 2021年12月15日 | 7314.73% | BTIG | →$15 | 升级 | 中性→购买 |
| 10/20/2021 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 10/19/2021 | - | BTIG | 评级下调 | 购买→中性 | |
| 12/16/2020 | 7314.73% | 瑞士信贷 | $9→$15 | 升级 | 中性→表现优异 |
| 12/07/2020 | 7314.73% | HC Wainwright公司 | →$15 | 开始承保 | →购买 |
| 11/11/2020 | 4348.84% | 瑞士信贷 | $8→$9 | 维护 | 中性 |
| 07/29/2020 | 3854.52% | 瑞士信贷 | $14→$8 | 维护 | 中性 |
| 2019年2月12日 | 14729.46% | BTIG | →$30 | 开始承保 | →购买 |
| 2019年2月12日 | 7314.73% | B of A证券 | →$15 | 开始承保 | →购买 |
| 2019年2月12日 | 9786.31% | 花旗集团 | →$20 | 开始承保 | →购买 |
| 2019年2月12日 | 6820.42% | 瑞士信贷 | →$14 | 开始承保 | →中性 |
What is the target price for Galera Therapeutics (GRTX)?
Galera治疗公司(GRTX)的目标价格是多少？
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by Citigroup on August 29, 2023. The analyst firm set a price target for $0.25 expecting GRTX to rise to within 12 months (a possible 23.58% upside). 8 analyst firms have reported ratings in the last year.
花旗集团于2023年8月29日报道了Galera治疗公司(纳斯达克：GRTX)的最新目标价。这家分析公司将目标价定为0.25美元，预计GRTX将在12个月内升至(可能上涨23.58%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Galera Therapeutics (GRTX)?
Galera治疗公司(GRTX)的最新分析师评级是多少？
The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by Citigroup, and Galera Therapeutics maintained their neutral rating.
花旗集团提供了对加莱拉治疗公司(纳斯达克代码：GRTX)的最新分析师评级，加莱拉治疗公司维持其中性评级。
When is the next analyst rating going to be posted or updated for Galera Therapeutics (GRTX)?
Galera治疗公司(GRTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Galera治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Galera治疗公司的上一次评级是在2023年8月29日提交的，因此您应该预计下一次评级将在2024年8月29日左右提供。
Is the Analyst Rating Galera Therapeutics (GRTX) correct?
分析师对Galera Treateutics(GRTX)的评级正确吗？
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a maintained with a price target of $0.40 to $0.25. The current price Galera Therapeutics (GRTX) is trading at is $0.20, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Galera治疗公司(GRTX)评级保持不变，目标价在0.40美元至0.25美元之间。Galera治疗公司(GRTX)目前的交易价格为0.20美元，超出了分析师的预测范围。